Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial

2012 ◽  
Vol 11 (12) ◽  
pp. 1029-1038 ◽  
Author(s):  
Jens Volkmann ◽  
Alexander Wolters ◽  
Andreas Kupsch ◽  
Jörg Müller ◽  
Andrea A Kühn ◽  
...  
2017 ◽  
Vol 43 (1) ◽  
pp. E2 ◽  
Author(s):  
Victor Goulenko ◽  
Paulo Luiz da Costa Cruz ◽  
Paulo Niemeyer Filho

Pallidal stimulation has been the usual surgical treatment for dystonia in the last decades. The continuous investigation of the physiopathology and the motor pathways involved leads to the search for complementary targets to improve results. The authors present the case of a 37-year-old woman who had suffered from idiopathic hemidystonia with hyperkinetic and hypokinetic movements for 11 years, and who was treated with deep brain stimulation. A brief literature review is also provided. The globus pallidus internus and the ventral intermediate/ventral oral posterior complex of the thalamus were stimulated separately and simultaneously for 3 months and compared using the Burke-Fahn-Marsden Dystonia Rating Scale and the Global Dystonia Severity Rating Scale, with a 3.5-year follow-up. The synergism of multiple-target stimulation resulted in a complete improvement of the mixed dystonic symptoms.


2013 ◽  
Vol 260 (9) ◽  
pp. 2417-2419 ◽  
Author(s):  
João Massano ◽  
Cláudia Sousa ◽  
Tom Foltynie ◽  
Ludvic Zrinzo ◽  
Marwan Hariz ◽  
...  

Neurology ◽  
2003 ◽  
Vol 61 (4) ◽  
pp. 546-548 ◽  
Author(s):  
J. C. Wohrle ◽  
R. Weigel ◽  
E. Grips ◽  
C. Blahak ◽  
H. H. Capelle ◽  
...  

2020 ◽  
pp. 185-194
Author(s):  
Mitesh Lotia

The past two decades have revealed substantial benefits of bilateral pallidal deep brain stimulation (DBS) in patients with medication-refractory primary dystonia. There is a growing body of evidence now describing not only short-term but also long-term benefits up to 10 years following DBS. These benefits are often sustained, requiring minimal long-term modification. Pallidal programming for dystonia may be complex owing to the gradual onset of benefits and often delayed development of side effects. There is a relative scarcity of evidence-based recommendations for standardized programming methods. This chapter reviews essential factors to consider for appropriate patient selection and discusses strategies for initial and follow-up programming. Finally, the chapter describes the potential short-term and long-term adverse effects, while considering various strategies to mitigate them.


2020 ◽  
Vol 35 (4) ◽  
pp. 629-639 ◽  
Author(s):  
Andrea Greuel ◽  
K. Amande M. Pauls ◽  
Anne Koy ◽  
Martin Südmeyer ◽  
Alfons Schnitzler ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-2 ◽  
Author(s):  
Lizl Lasky ◽  
Lindsay Bliss ◽  
Christos Sidiropoulos

Background. Dystonia is a ubiquitous syndrome, with a growing number of genes being continually identified. Mutations in the anoctamin-3 gene have been described to cause dystonia but the management and long-term outcomes are still largely unknown. Methods. We present here a long term, longitudinal follow up of a patient with generalized dystonia, who was treated with bilateral pallidal deep brain stimulation and was found to harbor a mutation in the anoctamin-3 gene. Results. Ongoing adjustment of stimulation settings and medications led to good and sustained dystonia control; however the patient did suffer short term relapses, manifested as dystonic crisis, which necessitated inpatient admission. Conclusion. This only the second patient to be reported with pallidal stimulation and an anoctamin-3 gene mutation. Long term outcomes seem to be favorable but larger case series are needed to confirm our findings.


Sign in / Sign up

Export Citation Format

Share Document